Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Health

FDA authorities set the stage for Merck’s molnupiravir approval in the U.S.

Staff Writer
Staff Writer 2 years ago
Updated 2021/12/03 at 2:49 AM
Share
SHARE

A panel of U.S. health advisers has set the stage for possible approval for the use of Merck’s molnupiravir to treat COVID-19.

According to an FDA report, a panel voted 13-10 with respect to the antiviral drug’s benefits outweighing its risks. The panel also took into consideration the potential for birth defects if consumed during pregnancy.

The move occurred amid the antiviral drug’s authorization in the UK, in which it became a first-of-its-kind pharmaceutical intervention thus far for combating COVID-19.

Merck’s findings of molnupiravir indicated that it may reduce the mortality risk by 30 percent among adults infected by the virus, becoming a promising intervention in the fight against mild-to-moderate cases of COVID-19.

“Merck’s drug uses a novel approach to fight COVID-19: It inserts tiny errors into the coronavirus’ genetic code to stop it from reproducing,” a news release reads. “That genetic effect has raised concerns that the drug could spur more virulent strains of the virus.”

The FDA is expected to make a decision on the distributional authorization of molnupiravir by the end of 2021.

Photo: Getty Images

You Might Also Like

Yoga practiced at home can help ease anxiety and boost memory

Conformity to the Mediterranean diet could be measured using a novel biomarker score

The connection between the mind and the body appears to be built into the brain

Older adults who are more active in their communities are less likely to need inpatient care

Higher levels of vitamin D during pregnancy linked to fewer behavioral problems in offspring

TAGGED: COVID-19, Merck, molnupiravir
Staff Writer December 2, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article 1 in 44 children have been diagnosed with autism in America: CDC data
Next Article How the dSlo2 channel may play a role in lessening epileptic seizures

Recommended

Health

Yoga practiced at home can help ease anxiety and boost memory

1 Min Read
Health

Conformity to the Mediterranean diet could be measured using a novel biomarker score

3 Min Read
Health

The connection between the mind and the body appears to be built into the brain

2 Min Read
Health

Older adults who are more active in their communities are less likely to need inpatient care

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?